Edition:
United States

Gilead Sciences Inc (GILD.O)

GILD.O on Nasdaq

70.48USD
22 Jun 2017
Change (% chg)

$2.98 (+4.41%)
Prev Close
$67.50
Open
$68.32
Day's High
$71.44
Day's Low
$68.29
Volume
28,962,895
Avg. Vol
8,599,493
52-wk High
$88.85
52-wk Low
$63.76

GILD.O

Chart for GILD.O

About

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS),... (more)

Overall

Beta: 1.23
Market Cap(Mil.): $88,204.16
Shares Outstanding(Mil.): 1,306.73
Dividend: 0.52
Yield (%): 3.08

Financials

  GILD.O Industry Sector
P/E (TTM): 7.14 244.33 18.98
EPS (TTM): 9.46 -- --
ROI: 29.63 -7.97 -5.09
ROE: 74.69 -9.96 -4.32

Gilead knocks out Merck patent on hepatitis C treatment

An appeals court handed biopharmaceutical company Gilead Sciences Inc a victory on Tuesday in its litigation with Merck & Co Inc over the blockbuster hepatitis C drug Sovaldi.

Jun 21 2017

BRIEF-Gilead receives approval in Canada for Vemlidy for treatment of chronic hepatitis b virus infection

* Gilead receives approval in Canada for Vemlidy™ (tenofovir alafenamide) for the treatment of chronic hepatitis b virus infection

Jun 19 2017

BRIEF-Gilead submits NDA for fixed-dose combination for HIV treatment

* Gilead submits new drug application to U.S. Food and drug administration for fixed-dose combination of bictegravir, emtricitabine and tenofovir alafenamide for HIV treatment

Jun 12 2017

Gilead and GSK go head-to-head with similar HIV drug data

(This story corrects story published on May 30 to show that two, not three, of the studies had enrolled previously untreated patients, in third and fourth paragraphs from the bottom.)

May 31 2017

CORRECTED-Gilead and GSK go head-to-head with similar HIV drug data

* Gilead integrase inhibitor proves just as effective as GSK's

May 31 2017

Gilead's HIV combination therapy succeeds in four late-stage studies

May 30 Gilead Sciences Inc said on Tuesday its combination treatment for HIV met the main goal in four late-stage studies, paving the way for regulatory submissions.

May 30 2017

BRIEF-Gilead says stockholders did not approve proposal requesting board take steps to adopt policy that chairman of board be independent director

* Gilead-Stockholders did not approve proposal requesting board take steps to adopt policy that chairman of board be independent director-sec filing Source text (http://bit.ly/2r9rtBo) Further company coverage:

May 12 2017

Gilead profit falls as hepatitis C sales drop, shares down

Gilead Sciences Inc on Tuesday reported a 25 percent drop in first-quarter profit as fewer patients were treated with its flagship drugs for hepatitis C, sending shares of the biotechnology company down 2.5 percent.

May 02 2017

UPDATE 2-Gilead profit falls as hepatitis C sales drop, shares down

May 2 Gilead Sciences Inc on Tuesday reported a 25 percent drop in first-quarter profit as fewer patients were treated with its flagship drugs for hepatitis C, sending shares of the biotechnology company down 2.5 percent.

May 02 2017

Gilead net profit falls 25 percent on lower hepatitis C sales

May 2 Gilead Sciences Inc on Tuesday reported a 25 percent drop in first-quarter profit as fewer patients were treated with its flagship drugs for hepatitis C, sending shares of the biotechnology company down 2 percent.

May 02 2017

More From Around the Web

Competitors

Earnings vs. Estimates